Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Vactosertib + Durvalumab for Bladder Cancer
Recruiting1 awardPhase 2
Buffalo, New York
This trial is testing a combination of two drugs, Durvalumab and Vactosertib, in patients with urothelial cancers who did not respond to previous treatments. Durvalumab helps the immune system attack cancer cells, while Vactosertib blocks signals that help cancer cells grow.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.